The global generic injectable market size was valued at 107.6 billion USD in 2022 and will grow with a healthy CAGR of 309.1% from 2022 to 2030, based on Precedence Research reports. Driven by increased demand for generic drugs from the health care sector and the customers enhanced.
Generic Injectables Market Key Takeaway:
- The large molecule type segment has held 69% revenue share in 2021.
- The small molecule segment accounted 31% market share in 2021.
- North America region has dominated the market with revenue share of around 46% in 2021.
The rapid acceptance of the generic injectables from the health care centre due to increased demands and the requirements due increasing prevalence of the chronic infectious disease across the regions drives the market growth with increased therapeutic index, with increased quality, strength, efficacy of the drug, dosage and route of administration similar to that of the patent branded drugs available in the market increased shortage of the new developments from the branded pharmaceutical led to increase the market rate of the generic injectables.
Increased research and development from the pharmaceutical companies for manufacturing and producing new generic injectables with increased efficacy with reduced adverse drug reactions with increased patient output contributes to expand the market of generic injectables with increased applications for various diseases with improved rout of administration and the containers utilized for the generic injectables. Increased government interest in developing the generic injectables with increased investment from the market enhanced the market growth to a larger extend.
Generic Injectable Market Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 107.6 Billion |
| Market Size by 2030 | USD 309.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 14.1% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product Type, Molecular Type, Application, Administration, Distribution Channel, and Geography |
| Companies Mentioned | DR. Reddys Laboratries Ltd, Baxter International, Mylan N.A, Teva Pharmaceuticals, Astra Zeneca Plc, Sanofi S.A, Fresenius Kabi, Pfizer Inc, Cipla Ltd, Merck & Co. Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Samsung Biologics Co Ltd, Biocon, Lupin,Ltd, Astrazeneca, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Cosette Pharmaceutical, Inc, Johnson & Johnson Services, Inc, Sanofi SA, Amgen Inc., Bristol- Myers Squibb Company, Piramal Pharma Solutions, Merck KGaA |
Generic Injectables Market Report Highlights
- By product type, monoclonal antibodies with increased market growth in the generic injectables.
- By molecule type, large molecule with increased market share for increasing the generic injectable production and manufacturing.
- By distribution channel, the hospitals with their own pharmacy such as hospital pharmacy with increased market rate of hospital pharmacy in the generic injectables.
Also Read: Sleep Aids Market Size Report 2022-30
Regional Snapshots
Generic injectables based on the geographical sector. North America to be largest region with increased market revenue share with increased demands from the market from health care centre with new developments and increased research from the market players enhanced the market growth of the generic injectables with high number of chronic infectious diseases spreading among the people with increased population across the nation which led to increased production and manufacturing of the generic injectables.
Asia Pacific region also contribute for increasing the market of the generic injectables due to low cost of the generic injectables enhanced the market growth with increased features and effectivity of the drug. Other regions such as Europe, Middle East and Africa, Latin America supports to enhance the market growth of the generic injectables with increased developments and demand from the market.
Generic Injectables Market Dynamics
Drivers
The advanced developed drugs developed across the regions with various developments and innovations with increased efficiency of the generic injectable with increased quality, efficacy, route of administration, reduced adverse drug reactions thrives the market growth of the generic injectables to a greater extend with increased demand from the health care center due increased chronic diseases enlarge the generic injectable market.
Faster approval of the generic as compared to that of the patent drug comes with the expiry of the patent. Therefore, reduced introduction of the new branded injectable drugs. Which led to increase demand from the market due to increased shortage of the injectables required with increased production and manufacturing of the generic injectables.
Cost effectivity is the major factor that drives the market with increased affordability of the generic drug for the common people with increased diseases among the people due to enhanced population and different diet intake affects the system of the human body with increasing chronic diseases led to demand for the generic injectable with increased hospitalization rate of the patients.
Increased continuous research and development with new introduction of the generic injectables with increased investment from the key market players in pharmaceutical industry fuels the market growth of the generic injectables with increased market revenue.
Restraints
Lack of awareness among the people regarding the generic injectables drugs available in the with increased cost effectivity may hamper the market growth of generic injectables. Increased cost during the production of the generic injectables with high cost of the equipments required during the manufacturing of the generic injectable drugs. Lack of interest for investing the funds for increasing the market of generic injectables and producing and manufacturing of the generic injectable may reduce the market growth.
Increased availability of the numerous options available other than generic drug with same content, equal efficacy of the drug, safety, quality could affect the market rate to grow high with increased generic injectables market share.
Opportunities
The rapid acceptance of the generic injectables due to increased availability of the generic injectables with enhanced research and development with new variations such as increased efficacy of the injectables, reduced side effect, increased safety of the injectables increased the market rate of the generic injectables, Increased chronic diseases such oncology to be leading disease with increased generic injectables requirement from the health care centre with increased number of chemotherapies.
Increased wide applications of generic injectables in various diseases for controlling and management of the disease. The increased number of market players for developing the generic injectables with increased production and new developments of the drugs enhanced the market rate during the forecast period.
Challenges
The increased cost for developing the generic injectables with increased cost during the production of the generic injectables with high cost of the equipments may decline the market growth of the generic injectables challenge the market to grow high. Increased cleanliness procedures during manufacturing of the generic injectables with increased sterilization process during production of the generic injectable drug with increased cost of the sterilization process to prevent from microbial attack and free from contamination of the generic injectable.
Lack of skill among the individuals for production of the generic injectables with increase in development may hault the market growth of the generic injectables. Increased availability of other drugs can challenge the generic injectables market to grow during the forecast period.
Recent Developments
- Cosette Pharmaceuticals Inc, introduced Prochlorperazine Edisylate drug infused similar to other drug such as Compazine injection of 10mg/2ml. IT is used in managing the queasiness and controlling the schizoprenia.
- Johnson & Johnsons and Midatech Pharma collaborated with each other in March 2022. Developing and increased focus for improving drug delivery technology with developments and increased research in biodistribution.
Market Segmentation
By Product Type
- Chemotherapy agents
- Small molecule antibiotics
- Vaccines
- Peptide antibiotics
- Blood factors
- Peptide hormone
- Insulin
- Cytokines
- Immunoglobin
- Monoclonal Antibodies
By Molecular Type
- Small Molecule
- Large Molecule
By Application
- Oncology
- Diabetes
- Infectious Diseases
- Blood Disorders
- Musculoskeletal Disorders
- Hormonal Disorders
- Pain Management
- CNS Diseases
- Cardiovascular Diseases
By Administration
- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generic Injectable Market
5.1. COVID-19 Landscape: Generic Injectable Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generic Injectable Market, By Product Type
8.1. Generic Injectable Market, by Product Type, 2022-2030
8.1.1. Chemotherapy agents
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Small molecule antibiotics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Peptide antibiotics
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Blood factors
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Peptide hormone
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Insulin
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Cytokines
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Immunoglobin
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Monoclonal Antibodies
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Generic Injectable Market, By Molecular Type
9.1. Generic Injectable Market, by Molecular Type, 2022-2030
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Generic Injectable Market, By Application
10.1. Generic Injectable Market, by Application, 2022-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Blood Disorders
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Hormonal Disorders
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8. CNS Diseases
10.1.8.1. Market Revenue and Forecast (2017-2030)
10.1.9. Cardiovascular Diseases
10.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Generic Injectable Market, By Administration
11.1. Generic Injectable Market, by Administration, 2022-2030
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Intramuscular (IM)
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Generic Injectable Market, By Distribution Channel
12.1. Generic Injectable Market, by Distribution Channel, 2022-2030
12.1.1. Hospital pharmacy
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Hospital pharmacy
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Drug stores
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Online pharmacy
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Generic Injectable Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.7. Market Revenue and Forecast, by Administration (2017-2030)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.10. Market Revenue and Forecast, by Administration (2017-2030)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. DR. Reddys Laboratries Ltd
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Baxter International
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.A
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Teva Pharmaceuticals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Teva Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Fresenius Kabi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cipla Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co. Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Immediate Delivery Available | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/2180
